Gram-positive bacteremia has a high morbidity and mortality rate of approximately 30%. Delayed diagnosis of clinically silent metastatic infectious foci is an important indicator for a complicated outcome. 18 F-FDG PET/CT allows detection of focal infection, resulting in lower relapse rates and mortality. Here, we present a cost-effectiveness analysis associated with introduction of 18 F-FDG PET/CT for patients with gram-positive bacteremia. Methods: A cost-effectiveness analysis in a

more »

... e 18 F-FDG PET/CT group (n 5 115) and matched control group (n 5 230) was performed alongside a clinical study, the results of which were previously published. Mortality at 6 mo was considered the final effect outcome and was used in the denominator of the incremental cost-effectiveness ratio. Results: Mortality in the 18 F-FDG PET/CT group was 19%, compared with 32% in the control group (P , 0.01). Incremental costs of 18 F-FDG PET/CT were $9,454 (95% confidence interval [CI], $3,963-$14,947), mainly because of admission (mean, $6,631; 95% CI, $1,449-$11,814). Additional costs were related to echocardiography (P , 0.01), not to 18 F-FDG PET/CT (P 5 0.8). The mean incremental costs of the 18 F-FDG PET/CT strategy estimated by stratification for endocarditis were $5,277 per patient (95% CI, $429-$10,123; P 5 0.03). The point estimate of the incremental cost-effectiveness ratio is $72,487 per prevented death (95% CI, $11,388-$323,379). Conclusion: Introduction of a diagnostic regimen including routine 18 F-FDG PET/ CT decreases morbidity and mortality. The cost increase is due to in-hospital treatment of metastatic infectious foci. Costs per prevented death, $72,487, are within the range that is considered to be efficient by Dutch guidelines. Patients with high-risk gram-positive bacteremia therefore should have easy access to 18 F-FDG PET/CT to enable early detection of metastatic infectious disease.